Medtech company
Every story that matters from the perspective of a medtech company, with one sentence on what it means for them specifically. 145 stories, latest first.
November 2026
FDA grants Breakthrough Device Designation to Cleo Skin AI pathology toolThe designation means faster dialogue with the regulator, but market authorisation still requires clinical evidence.Evident Vascular receives FDA approval for AI-powered IVUS imaging platformThe approval shows that AI can also be authorised in invasive imaging devices.FDA clears Neurotronics' AI-based sleep analysis softwareAnother 510(k)-type reference for the regulatory pathway of AI-based software products.FDA classifies digital cervical cytology slide imaging systems that use AI algorithmsThe classification determines the regulatory pathway and the evidence required to bring cytology AI tools to market.Study of 3,011 FDA warning letters finds seven citing AI, including earliest CDER letterCompliance preparation should include validating AI tools.Agilent completes Proscia acquisition for up to $270mDigital pathology is consolidating, with laboratory and diagnostics players integrating AI into their platforms.Stakeholders offer competing views on how FDA should regulate generative AI in medtechApproval strategies for generative AI products must be adjusted as the FDA's approach evolves.Senate draft bill seeks input on health AI oversight as FDA and CMS look to work with statesMulti-level oversight may bring differing requirements, so the legislative process must be followed.GE HealthCare adds two AI features to Vscan Air for cardiopulmonary triageAdding AI features to portable ultrasound is the direction of product competition.Senate draft would let Medicare test paying for AI that performs clinical tasks without real-time physician reviewIt could open a reimbursement path for autonomous clinical AI tools.
Oct 2026
Government decree on National Institute of Pharmacy monitors medical AI decision-support softwareFor AI and decision-support software entering the Hungarian market, the renewed regulatory competence must be clarified.AI agent reads emergency abdominal ultrasounds with 99.6% diagnostic accuracy in studyAI integration in ultrasound devices could become a competitive advantage.Hungarian and Argentine researchers improve uncertainty estimation in image-analysis AIUncertainty estimation could fit the reliability requirements for AI-based imaging tools.FDA clears Deep Reasoning AI's NeuroDR neurovascular CT angiography softwareThe 510(k) pathway remains viable for AI imaging software.NICE provisionally backs five AI tools for prostate cancer detection on MRI in the NHSThe interim funding route offers a model for market entry paired with evidence generation.ATA Action urges FDA to adopt risk-based framework for AI medical devices; policy proposal in the worksThe classification of generative AI devices and the change-management plan should be clarified at an early stage of development.EU AI Act high-risk rules pushed back to 2 December 2027The compliance timeline can be reworked, but joint planning for MDR and AI Act requirements is still needed.Cent raises $15 million Series A and acquires AI radiology platform MedseeIn the radiology AI market, acquisition is a route to scale.FDA-cleared AI devices pass 1,000, but their value in hospitals is unevenIn a crowded market, hospital integration and evidence will be the differentiators.Clarius launches 30 new AI models for handheld ultrasoundBundling AI models is becoming more important in the ultrasound device market.NICE backs interim NHS use of AI to review prostate MRI scansInterim NICE backing is a reference point for AI-based imaging software entering the UK market.Poland to join HealthAI global regulator network, second EU member to do soThe international regulatory network may bring approval practices closer together.Karolinska Institutet analysis asks who should decide when medical AI may be updatedOversight questions around updates point to regulatory solutions similar to PCCP-style plans.FDA clears MRI-based AI for mild cognitive impairment prognosis and Elucid's FFR-IQThe 510(k) clearances signal a path for further categories of imaging AI.AHA, AMA, ATA and radiology groups respond to FDA plan for generative AI medical devicesRisk-based classification, PCCPs and manufacturer accountability bear directly on the authorization plans for generative AI products.University of Texas System rolls out Abridge AI scribe at all eight health institutions; Australia tightens TGA oversightThe question of regulatory classification also affects how scribe products enter the market.FDA clears MRI-based AI tool to assess breast cancer recurrence riskThe clearance reinforces the regulatory pathway for prognostic imaging AI.MHRA promises closer FDA cooperation on AI medical devices at AdvaMed; Japan's PMDA shares principlesCloser FDA–MHRA cooperation and the PMDA principles may help companies plan multi-market clearance for AI devices.SimBioSys receives FDA clearance for AI breast cancer recurrence toolAnother example that prognostic software can also reach FDA clearance, a benchmark for companies' own submissions.FDA publishes discussion paper on generative AI-enabled medical devicesCompanies should submit comments before the deadline, as the discussion paper lays the groundwork for the future regulatory framework for generative AI devices.EU Biotech Act and the MDR–AI Act relationship divide the medtech sectorGiven the parallel compliance burdens under the MDR and the AI Act, companies should align their compliance plans with the current proposals.Agilent to acquire digital pathology firm Proscia for up to $270MThe wave of acquisitions among diagnostics players is creating competitive pressure.Scarlet raises $50M to build AI-native medical device certificationAI support in the certification process can shorten compliance work, but the quality of the provider needs to be verified.FDA has cleared more than 1,600 AI medical devices; warning letter flags software updatesThe FDA scrutinises change-management documentation for algorithm updates and cloud migrations.Children are left out of medical AI; a new method could helpPaediatric clearance is an untapped market niche.Four US states set different rules on whether AI can call itself a nurseProduct names must be checked state by state.Three-quarters of FDA-authorized AI medical devices are in radiology; real-world study finds more brain aneurysms detectedRadiology is the main area of AI authorizations, so competition is strongest here.FDA clears first AI test predicting breast cancer risk from a pathology slide; another risk tool available nationwideReaching patients directly raises new sales and regulatory questions.Australia's TGA regulates AI-based medical software as a medical deviceThe intended purpose of AI software determines whether it counts as a medical device, so this must be clarified before entering the Australian market.UK government accepts all 44 recommendations of national commission on AI in healthcare regulationAI-based devices must stay under continuous oversight after they reach the market, and the company must manage the device's development in line with the regulator.FDA outlines 2027 AI guidance plans; nurses can comment on generative AI framework until October 19Developers of generative AI devices need to follow the FDA framework, as it will shape future authorisation expectations.FDA clears AIRS Medical's AI MRI tool for body composition analysisThe clearance is another example of the regulatory pathway for AI applications built on MRI imaging.Lunit's breast imaging AI wins FDA clearance to automatically compare years of mammogramsThe clearance shows the regulatory feasibility of features that analyse patient history.FDA to prioritize guidance on AI and surgical robots next yearMust align AI and robotics product plans with the upcoming guidance.Czech startup Carebot raises record 36m crowns for AI diagnostic toolsIn the regional AI diagnostics market, the funding could mean a competitor or a partner.Everlywell offers Clairity's FDA-authorized AI breast cancer risk assessment nationwideThe distribution partnership offers a model for taking authorized AI tools to the consumer channel.How does an AI pathology tool become a companion diagnostic?The companion-diagnostic route opens a market opportunity for AI pathology tools.
September 2026
EU AI Act in healthcare: high-risk rules and deadlines in 2027 and 2028Must align MDR/IVDR conformity assessment with the AI Act's August 2028 deadline.Medical AI devices should be tested in real-world settings, but most in hospitals are notIt should collect performance data in clinical settings, including after authorisation.GE HealthCare hires Medtronic's AI leader as chief AI officerElevating AI strategy to the executive level signals competition among leading manufacturers.AI recommendations could help Britain carve its own path on medical device regulationCompanies entering the UK market must align with the distinct British regulatory route.FDA explores competency-based path for generative AI-enabled medical devicesShould comment on the framework and prepare for stricter evidence of intended use and clinical risk.AI speeds up hacking while local hospitals' defences remain weakMedtech companies must reduce known critical vulnerabilities in network-connected devices at the manufacturing end.Lunit wins contract for AI-supported breast cancer screening in StockholmThe large public procurement shows European demand for screening AI.FDA grant funds an LLM "jury" to evaluate AI-generated radiology reportsThe FDA's interest in evaluating report-generating AI signals future expectations.FDA clears AI devices: Tempus ECG tool, kidney stone surgery robot, CapsoCam featureThe clearances are model cases for AI devices going through the FDA pathway.New EU product liability rules extend to innovative medical devices and AIMust reassess liability exposure and the provability of its documentation.HUN-REN SZTAKI presents AI for premature infants' development at Singapore's Medical Fair Asia 2026Presenting domestic research institute developments at international exhibitions may open up market contacts.Commission defends AI medical device simplification plan after German warning; Hungarian analysis on classificationThe planned simplification and classification by intended purpose will determine the regulatory route for AI software, so companies should map the expected pathway now.AI model predicts pancreatic cancer risk three years before diagnosisPredictive models open a new development direction for cancers that are hard to screen for.Imaging AI: Incepto raises $16 million, UltraSight $24 millionCapital flowing into imaging AI intensifies product development and competition.a2z Radiology wins FDA clearance for CT AI, adding 10 findings to abdomen-pelvis triageThe expanded FDA clearance provides a reference point in the market competition for CT triage products.Study: AI could cut medical device recalls by nearly a thirdUsing AI tools in quality assurance and post-market data analysis could lower recall risk.FDA extends feedback period on generative AI medical device rules and tests language models on radiology reportsThe regulatory framework for generative AI devices is still taking shape, so companies should use the opportunity to comment.AI in cancer diagnostics: recurrence prediction, bladder cancer risk, oral tumours, a pathology engine and breast screeningBreast screening AI heading into final clinical trials and new pathology engines are sharpening product competition.EU AI Act high-risk deadline: medical devices follow the sector-specific conformity routeFor devices that contain AI, the sector-specific conformity process and the high-risk deadline are part of the design.Alibaba open-source AI model detects nearly 150 conditions, outperforming 23 of 26 radiologistsAn open-source model with broad coverage may put pricing pressure on closed vendors.FDA order keeps radiology AI under 510(k) premarket reviewRevenue for radiology AI remains tied to premarket clearance, so the 510(k) plan and documentation need to be maintained.FDA clears RadNet's foundation model-based chest X-ray AI toolClearance of a foundation model-based tool sets a precedent for similar developments.FDA publishes discussion paper on regulating generative AI-enabled medical devicesThe discussion paper is an opportunity to give feedback, so it is worth submitting expert comments.Medical devices from a One Health perspective: NNGYK IT department head on AIThis Hungarian public health forum stresses treating AI as a tool.Cognita wins $1.29 million FDA contract to evaluate radiology AIThe FDA is developing its methodology for evaluating radiology AI, which may shape future expectations.Powerful Medical's 'Queen of Hearts' AI ECG model wins FDA De Novo authorizationThe De Novo pathway creates a new product category, which serves as a reference for similar devices.GE HealthCare launches AI-driven operations systemDevice makers are also entering the market with operations-optimization software.UK commission publishes 44 recommendations on regulating AI in healthcare, from pre-market to lifecycleLifecycle-based oversight may foreshadow post-market monitoring obligations.Evidence for medical AI effectiveness is lacking: only 34 of 1,357 FDA-authorized devices registered for prospective studiesThe lack of prospective evidence is a market and credibility risk.US health officials deploy medical AI as safety concerns persistNo generative AI product for mental health has yet been authorized, which is both a market gap and a regulatory risk.Radiology accounts for 76% of FDA AI device authorizationsRadiology is the most crowded authorization area, and the FDA list can be used for competitor analysis.AI trained to think like pathologists may better detect cancer; new assistant reads whole slidesExplainable, step-by-step reasoning models can be a differentiator in the digital pathology market.FDA's PCCP lets AI devices update without a new clearanceA PCCP must be planned early in development, but it does not by itself resolve all AI lifecycle questions.Lunit and 10x Genomics to link AI pathology with spatial molecular dataPathology AI companies gain a partnership route toward multiomics platforms.AI analysis of pathology slides may help assess risk of pancreatic cancer recurrencePrognostic AI is another application area for diagnostic software.ARPA-H backs agentic AI for cardiovascular care, with awards to Atman Health and TempusARPA-H funding gives a competitive edge in autonomous cardiology AI.MHRA and Manchester NHS launch sandbox to test AI and health tech toolsThe sandbox offers real-world testing under regulatory supervision.UK commission: phased approval and new legislation needed for healthcare AICompanies entering the UK market should plan for post-deployment data collection because of the phased approval model.NHS begins largest surgical AI evaluation as Proximie rolls out AI cameras in operating theatresThe NHS evaluation could serve as a reference project for surgical AI vendors.Fewer than 1% of FDA-cleared AI devices tested for clinical benefitA lack of patient outcome data can be a competitive disadvantage in evidence-based purchasing.Global effort launched to overhaul regulatory framework for AI medical devicesHarmonisation efforts affect approval strategy across several markets.FDA weighs regulating AI devices like doctors as TEMPO pilot tests generative AIThe approval pathway for generative AI devices is taking shape in the TEMPO pilot; it is worth following the participation criteria.AI in breast screening can clear some mammograms without radiologist review, but clinical benefit is uncertainA standalone clearing function will require stricter evidence from regulators and buyers.Medicare sets new AI payment for radiology as Aidoc consortium faces NTAP analysisA payment code and NTAP status are the key to market entry in the US.Powerful Medical's AI heart attack detection model wins FDA approvalAnother example of the regulatory pathway for ECG AI.Ukrainian and US developers build AI tools for troops treating battlefield wounds without a medicRemote care without a doctor is an extreme use case for AI decision support.Vara receives world-first CE certification for autonomous AI in breast cancer screeningAutonomous diagnostic AI now has an EU regulatory pathway, which is also a benchmark for competitors.Bayesian Health's sepsis monitor wins Medicare new technology add-on paymentThe Medicare payment offers a template for the reimbursement strategy of AI tools.Manchester NHS and MHRA launch AI testing sandbox; MHRA commission publishes findingsThe sandbox gives AI tools a chance to be tested in a regulatory environment.OpenAI connects ChatGPT to Epic data for cliniciansThe linking of major EHR vendors with general-purpose AI platforms may narrow the space for standalone clinical AI tools, so interoperability strategy should be reviewed.South Korea's 2027 budget plan sets aside 1.26 trillion won for regional and essential healthcare, with more medical AIState funding for medical AI and robotics is a market opportunity.
August 2026
FDA pilot offers generative AI medical devices a path to patients before authorizationCompanies developing generative AI should examine whether to take part in the pilot and prepare for post-market monitoring.Hospitals' AI cyber risk: joint letter, report and medical device vulnerabilitiesMedical device security must be designed on the assumption that flaws can be found quickly with AI.EU AI Act deadline for medical devices reportedly moves to 2028, with two separate deadlinesCompliance roadmaps need to be re-planned, and companies must clarify which deadline applies to their product.Of 1,357 FDA-cleared AI devices, only three were tested on patientsThe lack of clinical validation risks tighter expectations from regulators and buyers.EU court ruling clarifies medical device definition for software and AIIntended-purpose wording and function should be reassessed, as they decide whether AI software qualifies as a device.AI is reshaping pathology as diagnostic investment growsInvestment flowing into pathology AI signals a market opportunity.AI analysis of mammograms can also detect heart disease in women, study suggestsSecondary risk estimation based on screening imaging is a new product area.FDA grants two breakthrough designations to generative AI radiology productsThe designation can mean expedited engagement with the FDA and is a reference point for radiology generative AI developers.London surgeons perform first AI-assisted brain tumour operation using real-time camera image analysisReal-time image analysis in the operating theatre is a development direction.Limbic selected for FDA pilot to test voice AI therapy with Medicare enrolleesThe FDA pilot shows the regulatory path for mental health AI products.Philips wins up to $33.7M ARPA-H award for AI-enabled robotic stroke careGovernment research funding is behind autonomous robotic interventions.Legal concerns raised over FDA's 'competency' approach to AI regulationGiven the legal uncertainty, compliance strategy and regulatory communication should be reviewed from a legal perspective too.Analysis: FDA's AI device list holds 1,430 authorized devices for 1995–2025The specialty distribution shows which clinical areas are crowded or still empty in the AI device market.FDA publishes discussion paper on regulating generative AI-enabled medical devicesCompanies should comment on the paper, because the planned guidance will set the authorization pathway for generative AI products.Radiology AI: cognitive biases, risks of ruling out findings and misidentified AI imagesTesting devices for human factors and biases is becoming an expectation in their evaluation.FDA clears two AI tools: pulmonary hypertension detection from ECGs and sepsis predictionCleared examples provide a reference for AI-based early-warning products.UCSF system gives confidence ratings to support brain tumour MRI analysisSignalling uncertainty can be a distinguishing feature of AI image-analysis products.Israel's regulatory sandbox tests autonomous AI in clinical careIt offers a testing opportunity for autonomous AI tools.Radiology Partners unit Mosaic petitions FDA on imaging AI regulationThe petition may affect the regulatory environment for imaging AI manufacturers.Craif raises $33M Series D for urine-based AI cancer testA new player in urine-based AI cancer screening has appeared on the U.S. market.FDA discussion paper would assess generative AI devices in a way similar to doctorsDuring the comment period, companies should indicate which tier of the proposed graduated assessment their product would fall into and what evidence they can provide for it.FDA has authorized more than 1,500 AI devices, but evidence is laggingGiven the evidence gap, companies should expect stronger demands for clinical substantiation.FDA's predetermined change control plan (PCCP) may play a growing role for AI devicesScheduled, pre-approved frameworks for model updates should already be planned at the time of submission.EU AI Act high-risk deadline pushed back 16 months; Health Canada clarifies status of AI scribesClassification under Annex I and Annex III must be re-planned around the new deadlines.Mayo Clinic AI detects pancreatic cancer signs on CT scans originally read as normalProspective validation is needed before market entry.Samsung develops AI models for continuous health monitoring on wearablesConsumer wearables are moving toward continuous health monitoring.CureMetrix receives FDA 510(k) clearance for cmAngio 2.0Clearance of a version update points to a direction of rapid iteration.Yale Pathology uses AI platform for prostate cancer diagnoses; Artera enrolls first DIRECT-AI registry patientThe registry is an example of real-world evidence generation for AI-based products.Aidoc's CARE Body CT Multi-Triage becomes eligible for Medicare new technology add-on paymentThe NTAP example shows that securing a reimbursement pathway needs to be built into the go-to-market plan.With no uniform rules, liability for healthcare AI errors remains unclearUnclear liability creates contractual and insurance risk for distributors.Leica Biosystems receives FDA clearances for AI-assisted quality control and digital pathology scannersCleared AI quality control sets a competitive benchmark in the pathology scanner market.Roen Surgical wins first FDA clearance for an AI-guided kidney stone robotThe first clearance sets a precedent for the regulatory pathway of surgical AI robots.Google Pixel Watch 5 adds AI health features; Abbott to build Google's AI health coach into glucose monitoringFor CGM and wearable makers, integrating an AI health coach is becoming a condition of competing.Some EU AI Act deadlines for healthcare AI and medical devices pushed back to 2028Companies need to assess which AI Act obligations already apply, which are postponed, and which relief measures have not been used.Aureka raises $100M Series B for AI drug discovery; Isomorphic Labs reportedly secures $2.1 billionFunding dynamics in AI drug discovery also affect the supplier ecosystem.Redesign Health study: 71% of health systems follow an 'Epic-first' AI purchasing strategyStartups must solve how to fit into the EHR vendors' ecosystems.FDA clears Ceribell's AI enhancements and outlines expectations for AI heart-monitoring wearablesDevelopers of wearable heart monitors should compare their product documentation with the expectations the FDA has set out.FDA advisory committee to review GRAIL's Galleri multi-cancer early detection testThe Galleri review is a precedent for the PMA pathway of similar AI-driven diagnostic tests.FDA's draft MDUFA VI commitment letter has implications for AI and digital healthCommitments tied to the user-fee cycle may affect the pace of review for AI-enabled devices, so the draft is worth reviewing.AI breast cancer screening: DBT scores, 2D mammography risk assessment, startup grantsEarly-stage companies are using grant funding to move toward regulatory approval.EU AI Omnibus now in force: AI requirements for medical devices postponed to 2 August 2028The compliance deadline for AI devices is 2 August 2028, so companies should also plan for the notified bodies' 28 January 2028 deadline in coordination with their certification body.London launches AI health regulatory sandbox for NHS innovation, MHRA seeks applicantsAI developers can apply to the MHRA sandbox for assessment before NHS deployment.FDA actions on AI tools: breast ultrasound, intraoperative margins, hidden heart disease, Aidoc First ReadThe clearance patterns offer guidance on the FDA pathway for similar AI tools.Leeds NHS innovation and Epredia partner to spread AI pathology globally; Cambridge start-up now in 15 NHS trustsNHS-level scaling offers an example of moving from a pilot to multi-trust deployment.FDA's July non-device software update and TEMPO AI pilot draw analysisThe device or non-device classification of AI apps needs to be reassessed in light of the FDA update.Aiforia secures €20 million EIB venture debt for AI diagnostics expansionThe EIB financing is an example of the capital-raising options open to European healthcare AI companies.Olea Medical and Median Technologies to bring AI lung cancer screening software to the US marketDistribution partnerships between imaging vendors and AI software makers can speed market entry.